This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
A tiny, four-fingered 'hand' folded from a single piece of DNA can pick up the virus that causes COVID-19 for highly sensitive rapid detection and can even block viral particles from entering cells to infect them, researchers report.
5c01712 Covalent small molecule drugs have emerged as a crucial support in precision therapy due to their high selectivity and robust potency. Covalent DNA-encoded chemical library (CoDEL) technology is an advanced platform for covalent drug discovery.
While molecular glue degraders exhibit drug-like properties, their discovery has traditionally been serendipitous and often requires post-hoc rationalization. [link] Targeted protein degradation (TPD) is an emerging therapeutic approach for the selective elimination of disease-related proteins.
At present, there are few studies on the drug resistance of mIDH1 inhibitors. It is found that a significant cause for drug resistance is that IDH1 has mutation at the second site. Isocitrate dehydrogenase (IDH) is a key metabolic enzyme that catalyzes the conversion of isocitrate to -ketoglutaric acid (-KG).
The modular structure of STAT3 nominates several of its protein domains as possible drug targets, but their exploitation with potential small-molecule inhibitors has been unevenly distributed so far, with past efforts highly favoring the conserved SH2 domain.
Currently, drugs and drug candidates against AR target the steroid-binding domain to antagonize or degrade AR. Nomura Journal of the American Chemical Society 2025 DOI: 10.1021/jacs.5c02801
Such alliances are already being operationalised, yielding innovations that accelerate diagnostic research in oncology, infectious diseases, reproductive health and other critical therapeutic domains, while simultaneously advancing NGS‐driven approaches for drug discovery. hours to 24 hours. Mybeckman.uk. 2025 [cited 2025 Jun 11].
The availability of safer anticancer drugs with exceptional selectivity for healthy cells and great efficacy against various cancer forms continues to be a significant obstacle. Piperazine also has a flexible binding feature that allows it to interact with a variety of biological targets, which makes it effective against cancers.
Current implementations typically involve piecemeal workflows where DNA sequencing is done one week, RNA expression the next, and proteomics later still. In drug discovery, where reproducibility, sensitivity and sample-limited contexts are paramount, these challenges pose significant barriers.
A personal journey to Alltrna Michelle Werner’s career has spanned over 20 years in the pharmaceutical industry, where she developed her expertise in oncology drug development at leading companies such as Bristol Myers Squibb, AstraZeneca, and Novartis. A single tRNA therapeutic could treat multiple diseases caused by the same mutation.”
The team has successfully created over 1000 of them, and each consist of: a harmless adeno-associated virus (or AAV) that acts like a shuttle capable of transporting specially designed DNA into the cell; a segment of DNA (an enhancer) that acts like an activation switch to mark or trigger a change in how the cell functions.
At the heart of radiopharmaceutical therapy is the ability to cause precise DNA damage within cancer cells, disrupting their ability to grow and divide. Image credit: Crystal Eye Media / Shutterstock The role of SPICA and manufacturing capabilities Drug development in the radiopharmaceutical space is particularly resource intensive.
Regulatory Guidance for Oligonucleotide Bioanalysis in Drug Development pmjackson Wed, 02/19/2025 - 21:30 The unique physicochemical properties of oligonucleotides require the use of specialized bioanalytical approaches, with key considerations including selectivity and specificity, sensitivity, stability, and matrix effects.
“Our mission as a company is to build the most impactful technologies that allow researchers and drug developers to understand underlying biology and ultimately use that to impact human health,” he says. From maths and physics to molecular biology Schnall-Levin did not begin in the life sciences.
For a contract research organization (CRO), it can play an integral role in increasing the quality and speed of drug development while reducing costs, repetitive manual tasks, and human error. My experience as an optimization scientist has shown how automation can be a valuable tool to support drug development for sponsors of all sizes.
Related groups Liu Group Related news New CRISPR genome editing system offers a wide range of versatility in human cells Researchers extend power of gene editing by developing a new class of DNA base editors In May 2025, researchers announced that K.J. To achieve that goal, we need a new framework for developing and approving drugs.
On April 10, 2025, the US FDA announced that it has a long-term plan to eliminate conventional animal testing in drug development, starting with monoclonal antibodies (mAbs).[ One great example is the FDAs 505(b)(2) New Drug Application (NDA) pathway. Legislation with delayed implementation In 2021, the FDA Modernization Act 2.0
4] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. [7] gmol 1 References ^ “Register of Innovative Drugs” Health Canada. 4] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. [7] Food and Drug Administration (FDA). 25 April 2023.
The ability of modifying RNA enabled us to sidestep many of the potential risks associated with permanent DNA editing. This ability to activate pathways could be possible for almost all proteins, however the biggest differentiation was to consider areas that were hard to drug – transcription factors, ion channels, intracellular proteins, etc.
Plastic leaves do not emit organic signals and contain no DNA, so any mimicry could imply some kind of primitive vision. Martin Bourdev is an engineer at Amgen Thousand Oaks supporting antibody drug production. He is from Palo Alto and is currently based in Los Angeles. Cite: Bourdev M. “Can Plants Really ‘See’?”
Certain CRISPR components can add short DNA sequences from the genomes of defeated viruses into the bacterium’s own genome, creating a type of protective “memory.” If the same virus invades the cell a second time, the gRNA’s spacer sequence will bind to the matching viral DNA sequence, then be cut by the Cas protein.
Art and technology often intersect in this way: a brush, a chisel, a 3D printer, DNA encoded with the image of a Germanic Rune , a biocompatible implant that induced the growth of an ear on a forearm, a bioprinter, CRISPR editing that induces pigmentation in bacteria. Each applied a different life-extension technique.
1428321-10-1 Pritelivir mesylate is an antiviral drug currently under development, specifically targeting herpes simplex virus types 1 and 2 (HSV-1 and HSV-2). Pritelivir (development codes AIC316 or BAY 57-1293 ) is a direct-acting antiviral drug in development for the treatment of herpes simplex virus infections (HSV).
In IDH-driven gliomas, the mutated IDH enzyme fosters the addition of methyl groups to the cells’ DNA. These chemical changes alter the expression of genes without modifying the underlying DNA sequence. Later in the disease, other genetic drivers that are not targeted by the drug take over.
This is an active drug development landscape with a lot of recent news. This drug received accelerated approval in December 2024 for pancreatic cancer and non-small-cell lung cancers (NSCLC) carrying NRG1 gene fusions, only 11 years after the first NRG1 gene fusion paper was published ( [link] ). months (see [link] ).
For example, once considered incurable and terminal, patients with sickle cell disease may reach new summits in their lives with gene editing technologies such as CRISPR to repair affected DNA and, in some cases, functionally cure the condition. There are also nuances for operational planning in cell therapy development programs.
Whether it is determining concentrations of molecules like proteins or DNA, looking at enzyme kinetics for crucial reactions, or measuring something as fundamental as cell growth, you will find references to absorbance or optical density measurements. Optical density is also widely used for many scientific applications.
For adeno-associated viral vectors, examples may include characterization of non vector DNA impurities in capsids by next-generation sequencing, vector genome size analysis, and detection of capsid amino acid modifications by mass spectrometry.
The tumor microenvironment can also impact drug efficacy, while strict eligibility criteria can limit the pool of potential participants, affecting the generalizability of study findings.
Learn More > Variant Libraries Order Now TCR Libraries New Combinatorial Variant Library Spread Out Low Diversity Libraries Site Saturation Libraries Enzyme Screening Kits New Watch how Twist builds variant libraries for your perfect application Synthetic Controls Order Now Liquid Biopsy cfDNA Pan-Cancer Reference Standards v2 New Infectious Disease (..)
We welcome opportunities to engage with the rare disease community and help contribute to the conversation between advocates, researchers, drug developers, and more. For any collaboration inquiries or questions about the 2025 Rally for Rare event, reach out to rare@worldwide.com.
Author Sean Harrison spent months tracking down original translations and primary sources to unpack the history behind one of the world’s most prescribed drugs, only to discover that many commonly referenced texts are likely wrong. Issue 07 launches this Monday with a marvelously researched essay on the uncertain origins of aspirin.
Researchers describe the steps they took to manipulate DNA and proteins -- essential building blocks of life -- to create cells that look and act like cells from the body. This accomplishment, a first in the field, has implications for efforts in regenerative medicine, drug delivery systems and diagnostic tools.
A DNA-encoded chemical library (DEL) screen against Bfl-1 identified the first known reversible covalent small-molecule ligand for Bfl-1. This represented the first identification of a cyano-acrylamide reversible covalent compound from a DEL screen and highlights further opportunities for covalent drug discovery through DEL screening.
“Meet Invisible Woods: a clean, refreshing scent revived from extinct flower DNA ,” beneath an image of “origin flower” Wendlandia angustifolia. • compare the DNA sequence to similar genes in other species. • tweak a lab-made copy of the DNA sequence using clues from other plant species.
The Facility will have capacity that exceeds today’s global plasmid DNA demand and can enable commercialisation of genetic medicines. Transformation of Grade II-listed Victorian waterworks on the River Thames in Hampton, London.
There is extensive crosstalk between the DNA damage response (DDR) and innate immune pathways. Both are a focus for exciting new small-molecule drug therapeutics that target cancers and autoimmune disorders.
SM cytotoxicity emerges, in part, through DNA alkylation and double-strand breaks (DSBs). Because DSBs can naturally be repaired by DNA damage response pathways with low efficiency, we hypothesized that enhancing the HR pathway could pose a novel approach to mitigate SM injury.
It was found that combining these drugs with lower doses and for shorter treatment periods induced greater or equal toxicity in cancer cells than using either as a single agent. Here, we develop a mathematical model to investigate the effects of ceralasertib and olaparib, two drugs that target DNA damage response pathways.
Whitehurst, Hua Xu, SLAS Discovery, 2024 [link] Covalent hits for drug discovery campaigns are neither fantastic beasts nor mythical creatures, they can be routinely identified through electrophile-first screening campaigns using a suite of different techniques. Employing best practice, however, is critical to success.
DNA methylation is a highly studied epigenetic modification that regulates genome function and plays key roles in development and disease1. EpiCyphers novel meCUT&RUN workflow leverages ultra-sensitive, low-cost DNA methylation profiling for translational research and drug discovery.
Instead of the black, printed stripes of the Universal Product Codes (UPCs) that we see on everything from package deliveries to clothing tags, they used short, unique snippets of DNA to label cells. DNA barcoding has already empowered single-cell analysis, including for nerve cells in the brain. PRISM consists of two key components.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content